X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AZR-MD-001 is an easy-to-use ophthalmic ointment preparation applied directly to the meibomian glands in the lower eyelid. It is under phase 3 clinical development for the patients with Contact Lens Discomfort (CLD) & Meibomian Gland Dysfunction (MGD).
Lead Product(s): Selenium Sulfide
Therapeutic Area: Ophthalmology Product Name: AZR-MD-001
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
AZR-MD-001 0.5% meets co-primary efficacy endpoints, making it the first investigational drug to show significant improvements in both signs and symptoms of Meibomian Gland Dysfunction.
Lead Product(s): AZR-MD-001
Therapeutic Area: Ophthalmology Product Name: AZR-MD-001
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2022
Details:
AZR-MD-001 harnesses the power of selenium sulfide (SeS2) in an easy-to-use ophthalmic ointment preparation applied directly to the meibomian glands on the eye lid.
Lead Product(s): AZR-MD-001
Therapeutic Area: Ophthalmology Product Name: AZR-MD-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2022
Details:
The grant will support Azura’s two-stage study evaluating the safety, tolerability and efficacy of the company’s lead clinical candidate, AZR-MD-001, in patients with contact lens discomfort (CLD) who show evidence of Meibomian gland dysfunction (MGD).
Lead Product(s): AZR-MD-001
Therapeutic Area: Ophthalmology Product Name: AZR-MD-001
Highest Development Status: Phase II/ Phase IIIProduct Type: Undisclosed
Partner/Sponsor/Collaborator: CUREator
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding September 07, 2022
Details:
On the back of encouraging Phase 2 data to date proceeds from the funding round will be used to advance Azura’s lead product candidate AZR-MD-001 through a registration study for the treatment of MGD.
Lead Product(s): AZR-MD-001
Therapeutic Area: Ophthalmology Product Name: AZR-MD-001
Highest Development Status: Phase II/ Phase IIIProduct Type: Undisclosed
Partner/Sponsor/Collaborator: OrbiMed
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Financing October 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
